a Objective: To evaluate whether interleukin (IL)-2 in patients with chronic HIV infection can maintain CD4 T cell counts during 6 months of HAART interruption.
HAART has dramatically improved the outcome of HIV infection [1] [2] [3] but can be associated with high costs, medication fatigue, and adverse effects, including hepatotoxicity [4] and a metabolic lipodystrophy syndrome involving insulin resistance, hyperlipidemia, and fat redistribution [5, 6] . HAART interruption strategies In attempts to abrogate CD4 T cell losses and reemergence of HIV viremia seen with HAART interruption, immunomodulatory approaches, including interleukin (IL)-2 cytokine therapy, have been evaluated. When used with antiretroviral agents (ARV), intermittent courses of intravenous or subcutaneous IL-2 can significantly expand the CD4 T cell pool in HIV-infected patients [13, 14] . This results primarily from increased survival of naive [15, 16] and central memory [17, 18] CD4 T cells, including a cytokine-expanded naive CD4 þ
CD25
þ FoxP3-expressing subset, which resembles regulatory T cells [19, 20] . Two international, multicenter, phase III clinical trials [Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT), Study of IL-2 in People with Low CD4 þ T Cell Counts on Active Anti-HIV Therapy (SILCAAT)] are currently underway to determine the clinical relevance of these IL-2 effects with regard to HIV disease progression [21, 22] .
In addition to its adjuvant role in ARV therapy [13, [23] [24] [25] , IL-2 has also been studied with therapeutic immunization [26, 27] and in the absence of ARV [14, [28] [29] [30] . The potential role of IL-2 during HAART interruption was studied in AIDS Clinical Trials Group (ACTG) 5102 [28] , which evaluated IL-2 recipients versus nonrecipients with chronic HIV infection following HAART interruption. Although higher CD4 T cell counts were observed with IL-2, no differences were noted in virologic rebound or in the time for CD4 T cell counts to fall below 350 cells/ml. The kinetics of CD4 T cell expansion with IL-2 was were also studied in a selfpaired National Institutes of Health (NIH) cohort of HIV-infected patients -first, in the presence of continuous HAART and, second, followed immediately by HAART interruption. This revealed short-term CD4 T cell count increases in both settings, although to a lesser extent with HAART interruption [29] .
The present study (ICARUS or Interrupted versus Continuous Antiretrovirals involving Randomization from the Umbrella Study) was a randomized, controlled trial in which HIV-infected, IL-2-experienced patients first underwent a baseline IL-2 cycle on HAART and were then randomized to either HAART interruption and intermittent IL-2 therapy or continuous ARV for a minimum of 6 months. The ability of IL-2 to maintain CD4 T cells off HAARTwas evaluated, as well as whether 6 months of HAART interruption could mitigate ARVassociated lipodystrophy syndrome, reduce hepatotoxicity, and improve quality of life. Forty men and one woman with HIV-1 infection were  recruited between September 2002 and June 2005, primarily from an NIH IL-2-recipient follow-up protocol [14] . Inclusion criteria were a minimum of three preenrollment IL-2 cycles, a CD4 T cell count at least 500 cells/ml, and willingness to interrupt or maintain HAART for 6 months, per randomization. Exclusion criteria included chronic hepatitis B, participation in other HAART interruption studies within the previous 6 months, malignancy requiring chemotherapy within the past 2 years, HIV complications necessitating ongoing HAART, and multidrug-resistant HIV requiring salvage ARV therapy. The study was approved by the National Institute of Allergy and Infectious Diseases (NIAID) Institutional Review Board (IRB), and all participants signed informed consent.
Methods Participants

Study design
The ICARUS study was a prospective, controlled, openlabel phase II noninferiority trial. All participants received a baseline cycle of subcutaneous IL-2 upon enrollment [3-7.5 million international units (MIU) twice daily for 5 days] at the highest tolerated dose from their last IL-2 cycle. Participants were then randomized 2 : 1 to interrupt or continue HAART, using a permuted block design with masked block size. For HAART interrupters, nonnucleoside reverse transcriptase inhibitors were stopped 2 days after the baseline IL-2 cycle, with all other ARV discontinued a week later. All participants had monthly clinical and laboratory evaluations. After the 6-month primary study period, HAART interrupters could continue this intervention over a 6-month extension phase, whereas participants randomized to continuous HAART could crossover to interrupt ARV (i.e., late HAART interrupters) for the next 6 months or end study participation.
Over the entire 12-month study period, intermittent courses of IL-2 were given up to every 8 weeks to participants in either group, if consecutive CD4 T cell counts drawn at least 1 week apart declined to less than 90% of baseline, allowing for a maximum of three additional IL-2 cycles during the 6-month primary study phase. HAART could be restarted at any point according to patient's desirability, clinical indication, or if CD4 cell count fell to less than 350 cells/ml on two occasions within 8 weeks of receiving an IL-2 cycle. HAART interrupters received 10 days of non-abacavir protease inhibitor-based HAART with each 5-day IL-2 cycle, starting 3 days before and stopping 2 days after its completion, to abate possible IL-2-induced HIV replication [31, 32] .
The primary outcome measure was CD4 T cell count at month 6 (and at least 4 weeks after the last IL-2 cycle), with treatment success defined as maintaining randomization assignment and having a CD4 T cell count at least 90% of baseline. Secondary end-points included HIV viral load at month 6, treatment success at month 12, and rates of change in CD4 T cells and HIV viremia following HAART interruption.
Study medications
Recombinant human IL-2 was provided by Novartis (Emeryville, California, USA). ARV usage was recorded and monitored throughout the study.
Immunologic parameters CD4 and CD8 T cell counts (total and percentage) were measured monthly in a Clinical Laboratory Improvement Amendments-approved laboratory. CD4 þ CD25 þ T cells (previously shown to expand with IL-2 [33] ) and peripheral blood mononuclear cell (PBMC) 3 H-thymidine proliferation assays using HIV p24, tetanus toxoid, and phytohemagglutinin [34] were also followed.
Virologic parameters
HIV viral load was measured by ultrasensitive branched DNA assay (bDNA version 3, Chiron Corporation, Emeryville, California, USA) with a lower detection limit of 50 copies/ml. HIV genotyping (TRUGENE, Visible Genetics Inc., Suwanee, Georgia, USA) was performed at baseline or a preenrollment time point with HIV RNA more than 1000 copies/ml, the initial time point with similar viral rebound following HAART interruption, and at end-of-study or prior to resuming ARV (whichever occurred first) to check for new resistance mutations, using TRUGENE Guidelines. Additional preenrollment genotypes were completed as needed to determine whether mutations were preexistent, though not detected at baseline. Participants who remained off HAARTafter end-of-study were followed up to 4 years to assess their capacity to suppress HIV viremia upon restarting ARV.
Metabolic function and quality of life measures
Metabolic indices measured at baseline and month 6 included external body composition (weight; BMI; % body fat; multisite skinfold widths, including suprailiac, subscapular, biceps, triceps, calf, and abdomen; limb circumferences for forearm, mid-arm, calf, and thigh; body widths at the hips, waist, abdomen, and neck) and both subcutaneous and visceral adiposity determined via single-slice axial computed tomography at lumbar vertebral levels 2-3 and 4-5 [35] . Markers of endocrine and hepatic function included total cholesterol, highdensity lipoprotein, low-density lipoprotein, fasting triglycerides, apolipoprotein A1 and B, glycosylated hemoglobin (HgbA1c), oral glucose tolerance testing (75 gm bolus), thyrotropin, free and total thyroxine, triiodothyronine, reverse triiodothyronine, uric acid, Llactate, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, and total bilirubin. The MOS-HIV Health Survey, an established tool in HIV-related quality of life research [36] [37] [38] , was also administered.
Statistical considerations
Both intent to treat and per protocol analyses were performed. For the primary study end-point, the likelihood score method [39] was used to determine a two-sided 90% confidence interval (CI) to estimate the difference in proportions of participants with treatment success between interrupted and continuous HAART groups at month 6. The target sample size of 65 participants would have provided 79% power to obtain a lower confidence limit greater than À0.2 for P (interrupted) À P (continuous), assuming 90% treatment success and 10% attrition [equivalent to 79% power to reject H 0 : P (interrupted) À P (continuous) À0.2 at a one-sided 5% significance level]. Due to slow recruitment, enrollment was closed at 41 participants, providing 80% power for two-sample t-tests of laboratory parameters with an effect size at least one SD at a twosided 5% significance level. Mann-Whitney and Wilcoxon signed-rank tests were used for nonparametric median comparisons between and within groups, respectively, whereas Fisher's exact test was used for proportional comparisons.
Safety assessments
Safety monitoring was completed via interview and laboratory assessment, following the Food and Drug Administration adverse event criteria and NIAID IRB guidelines. Adverse events were graded on a predetermined toxicity scale from 0-4.
Results
Study participants
Protocol flow of study participants is summarized in Fig. 1 . Demographic and baseline characteristics are shown in Table 1 .
Interleukin-2 cycling and HAART resumption
Following the baseline IL-2 cycle, the need for additional on-study IL-2 cycling triggered by CD4 T cell counts less than 90% of baseline differed between the groups, with eight (29.6%) HAART interrupters receiving a single IL-2 cycle each during the primary phase (median of 52.5 MIU per participant) and 15 (51.9%) receiving a total of 17 cycles during the secondary phase (median of 45 MIU per participant). In contrast, no one in the continuous HAART group required IL-2 during the primary phase and only three (30%) late HAART interrupters received a single IL-2 cycle each during the secondary phase (median of 45 MIU per participant).
No early HAART interrupters restarted ARV during the primary phase, although six (22.2%) restarted during the extension phase due to falling CD4 cell counts or rising HIV viremia, and one restarted after end-of-study due to a B cell lymphoma. By comparison, two (20%) late HAART interrupters restarted ARV while on-study ( Fig. 1) due to an acute ARV syndrome and a case of secondary syphilis, with another restarting at end-ofstudy for recurrent Kaposi's sarcoma. Of the remaining participants, all but two early and two late HAART interrupters restarted ARV after end-of-study due to decreased CD4 cell counts or increasing viremia.
Primary outcome: treatment success at month 6 A larger proportion of participants (92.3%) in the continuous HAART group maintained CD4 T cell counts within 10% of baseline at month 6 (the primary study end-point), compared with HAART interrupters [48.1%, P ¼ 0.013, Fisher's exact test] ( Table 2 ). The 95% CI for the difference in these proportions (from À64.2 to À11.2%, interrupted-continuous) had a lower limit well below the predetermined noninferiority standard of À20%. Figure 2a depicts lower median CD4 T cell counts in interrupted in comparison with continuous HAART groups throughout the primary study phase and at month 6 (P < 0.001). Thus, IL-2 with HAART interruption was inferior in terms of treatment success at month 6, compared with IL-2 with continuous HAART.
One participant in the continuous HAART arm withdrew from the study after 4 months in order to stop ARV. Inclusion of that participant as a treatment nonsuccess gives P value 0.041 for the difference in treatment success rates, and the noninferiority criterion is still not met. As month 6 data are unavailable for that participant, he was excluded from all other analyses.
Secondary metabolic and quality of life analyses No significant differences were observed in anthropometric indices between the interrupted and continuous HAART groups at baseline or month 6 (Mann-Whitney test; data not shown). For laboratory measures (Table 3) , significantly lower values were seen at month 6 in the interrupted compared with continuous HAART group for total cholesterol (161 versus 190 mg/dl, P < 0.05) and apolipoprotein A1 (98.5 versus 111 mg/dl, P < 0.05). In contrast, HgbA1c was significantly higher in HAART interrupters at month 6 (5.4 versus 4.95%, P < 0.001). However, medians in both groups at baseline and month 6 were within normal range (<6%).
Physical and mental health scores on the MOS-HIV did not differ significantly between the groups at either time point (data not shown). However, the change in score from baseline to month 6 on the Energy/Fatigue subscale 
Rates of change in HIV viral load and CD4 T cell count
Logistic regression analysis was used to calculate median rates of change in HIV viral load and CD4 T cell count over the first 6 months of HAART interruption, using all data points until first HAART reexposure (i.e., either IL-2 cycling or resumption of HAART). To evaluate the effects of timing of HAART interruption relative to the baseline IL-2 cycle, median rates of change were compared between early and late HAART interrupters. No significant difference in rate of HIV viral load increase was seen (early: 6356 copies/ml per month, late: 1162 copies/ml per month; P ¼ 0.16; Mann-Whitney test). However, the rate of CD4 T cell decline was steeper in late (À96 cells/ml per month) than in early (À38 cells/ml per month) HAART interrupters (P < 0.001), indicating that 6 months of HAART following a baseline IL-2 cycle did not mitigate and, in fact, may have exacerbated this decline (Fig. 2b) . Median rates of change were also compared in intragroup analyses within early or late HAART interrupters between subjects considered treatment successes versus nonsuccesses. Within early HAART interrupters, although the rates of HIV viral load increase did not differ significantly (nonsuccesses: 7631 copies/ml per month, successes: 3174 copies/ml per month; P ¼ 0.20), treatment nonsuccesses had a steeper CD4 T cell decline compared with treatment successes (77 versus 3 cells/ml per month; P < 0.001; Fig. 2c ). Similar comparisons among late HAART interrupters did not reveal any significant differences (data not shown).
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T cell phenotype and function
The percentage of CD4 þ CD25 þ T cells did not differ between the groups at baseline (17% for both groups, P ¼ 0.77) but was significantly lower in HAART interrupters at month 6 (18 versus 29%, P ¼ 0.018). No significant differences in PBMC proliferative responses to HIV p24, tetanus toxoid, or phytohemagglutinin were observed between interrupted and continuous HAART groups or early and late HAART interrupters during the primary or secondary phases (data not shown). Proportional (Fisher's exact test) and median (Mann-Whitney test) comparisons were done to identify predictors of treatment success in either early or late interrupters, including baseline HIV viral load less than 50 copies/ml, peak on-study HIV viral load, nadir and baseline CD4 T cell counts, %CD4, and %CD4 þ CD25 þ T cells. Only nadir CD4 count in early HAART interrupters significantly differed between treatment successes (422 cells/ml) and nonsuccesses (248.5 cells/ml; P ¼ 0.023).
Safety assessment
Grade 3 adverse events were constitutional symptoms previously reported with IL-2 therapy [40] , including fatigue (n ¼ 8), fever (n ¼ 2), and abdominal pain (n ¼ 2). The only Grade 4 event was an episode of transient hyperbilirubinemia due to underlying Gilbert's syndrome. Significant clinical events were detailed in the section on HAART resumption.
HIV genotypic analysis indicated no novel resistance mutations emerged following HAART interruption, although two changes were noted. An early HAART interrupter with a reverse transcriptase T215Y change prior to enrollment developed a T215NTDA mutation, which reflects preexisting polymorphisms in ARV-naive individuals, as reversion from T215Y often occurs after HAART interruption. Another common polymorphism in ARV-naive individuals (protease I15V mutation; Stanford HIV Drug Resistance Database [41] ) was observed in a late HAART interrupter. All participants who restarted HAART had virologic suppression to less than 50 copies/ml, except for two who continued treatment interruption beyond end-of-study: the first had documented medication nonadherence and the second had no prior HIV viral loads of less than 50 copies/ml, though after restarting HAART, his viral load decreased by more than 1 log from 9742 to 781 copies/ml.
Discussion
The present prospective, randomized trial demonstrated IL-2 alone was inferior in maintaining CD4 T cell counts at least 90% of baseline in IL-2-experienced recipients after 6 months of HAART interruption, compared with IL-2 along with HAART. Despite a baseline IL-2 cycle administered in the setting of moderate to high CD4 T cell counts (range: 538-1390 cells/ml) and largely suppressed HIV viremia, this immune intervention could not sufficiently overcome the CD4 T cell declines associated with HAART interruption, as compared with patients who received IL-2 and remained on HAART.
Several phase II studies [13, 18, 24, 25, 42] have documented IL-2 dose-dependent expansions of CD4 T cells, with increases in naive and memory subsets due to improved survival and decreased immune activation when administered with HAART. The immune restoration conferred by HAART alone is incomplete, however, despite reductions in CD4 T cell activation, turnover, and lymphopenia [43] [44] [45] [46] . Thus, significant interest remains in IL-2 to augment the benefits of HAART by further reducing immune activation [47] , as changes in plasma HIV RNA explain only 3-6% of the variability in CD4 T cell loss [48, 49] .
Regarding its use with HAART interruption, the results of Agence Nationale de Recerche sur le Sida (ANRS) 095 [50] and ACTG 5102 [28] suggested IL-2 conferred no benefit to HIV-infected persons, regardless of whether ARV were initiated during primary infection or later in the disease. Nonetheless, earlier data from the ICARUS cohort comparing preenrollment and baseline IL-2 cycling indicated CD4 T cell increases were achievable with IL-2 followed by HAART interruption [29] .
The recently published TILT trial demonstrated IL-2 could reduce the probability of restarting ARV by 50% following 2 years of HAART interruption [51] . The different conclusions in ICARUS and TILT may be explained by the stricter criterion for treatment success used in the former. Whereas we sought to maintain CD4 T cells within 10% of baseline levels (947 cells/ml), in TILT, IL-2 cycles were triggered by CD4 T cell counts less than 350 cells/ml, and HAARTwas restarted for CD4 T cell counts less than 200 cells/ml [51] . In fact, CD4 T cell increases following IL-2 with HAARTwere similar in these studies, with half the HAART interrupters in ICARUS qualifying as treatment successes at month 6. This occurred despite the potential for self-referral bias within the ICARUS cohort of patients who tolerated IL-2 well and had high baseline CD4 T cell counts.
As in past studies [28, 52, 53] , higher CD4 T cell nadirs were associated with treatment success (i.e., higher CD4 cell counts) in the ICARUS cohort, although baseline CD4 cell count [52, 54] and HIV viral suppression [52] were not. Whereas lack of CD4 þ CD25 þ T cell expansion in early HAART interrupters suggested the importance of viral suppression in the IL-2-induced expansion of this subset [19, 20, 33] , delaying HAART interruption for 6 months after a baseline IL-2 cycle was not more successful in maintaining CD4 T cells, despite greater CD4 cell count increases and prolonged viral suppression prior to interruption. This was reflected in similar treatment success rates in early and late HAART interrupters, with a steeper CD4 cell count decline in the latter (À96 cells/ml per month), similar to previous studies [28, 55] . By comparison, CD4 declines in IL-2-naive patients following HAART interruption range widely in the literature from À10 to À200 cells/ml per month [28, [55] [56] [57] .
Six months of HAART interruption in our study also provided little benefit to HAART interrupters, with only small decreases in total cholesterol (similar to ACTG 5102 [58] ) and apolipoprotein A1. Although HgbA1c was lower in the continuous HAART group at month 6, the clinical relevance of this is unclear, as values in both groups remained within normal range. This may reflect the expected increase in erythrocyte life span after stopping nucleoside reverse transcriptase inhibitors and reducing subclinical hemolysis [59] . A small (10% median group difference) though significant increase in energy level from baseline to month 6, as measured by the MOS-HIV Health Survey, was also observed in interrupted compared with continuous HAART participants, indicating IL-2 cycling (which was more frequent in HAART interrupters) did not adversely affect this quality of life measurement.
The findings of the ICARUS trial showed that IL-2 alone was inferior in maintaining baseline CD4 T cell counts after 6 months of HAART interruption, compared with IL-2 along with HAART. In the post-SMART era [11] , HAART interruptions are of limited scope and conducted under close supervision in clinical trials. However, adjunctive therapies to limit HAARTexposure and abrogate the chronic inflammation of HIV infection (presumed to be a major cause of non-HIV-related complications [12, 60] ) merit exploration. Studies are underway to evaluate the capacity of IL-2 to delay HAART initiation in early HIV infection (STALWART) [61] , and preliminary data from ANRS 119 suggest IL-2 can delay CD4 T cell decline and prolong time to an AIDS-defining event or HAART initiation in ARVnaive individuals [62] . Although unlikely to be of value as part of a HAART interruption strategy, the clinical impact of IL-2 in HIV disease will become clearer with the availability of data from the ESPRIT and SILCAAT trials.
